Plain-English translation of NCT07860580 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying three specific substances in the blood—alpha-tectorin, interleukin-10, and thiol-disulfide markers—to better understand congenital hearing loss (hearing loss present from birth). This study will compare these blood markers in children who were born deaf or hard of hearing and use either cochlear implants or hearing aids, alongside healthy children with normal hearing. The goal is to learn whether these markers might help explain why some children are born with hearing loss.
Currently, doctors don't fully understand all the biological reasons why some children are born with hearing loss. By studying these specific blood markers across different groups, researchers hope to identify clues that could eventually lead to better prevention, earlier detection, or new treatments for congenital hearing loss.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital outpatient clinic once for a routine appointment. A healthcare provider will collect about 5 milliliters (roughly 1 teaspoon) of blood from your arm using a standard needle, similar to a regular blood test. Your age, medical history, hearing loss details, and information about any devices you use will be recorded. The blood will be analyzed in the laboratory, and you should not expect any follow-up visits.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Turkey (Türkiye)